Entrada Therapeutics, Inc.
TRDA · Pharmaceutical Preparations · 38.8M shares · +144%/yr ↑ dilution · EDGAR filings ↗
Reference price $5.86 · est. market cap ~$228M — last insider purchase, 2026-05-20 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D44Clinical/early-stage biotech — intracellular-therapeutics clinical, heavy burn ($130M), funded.
Strengths
- Liquidity — current ratio 12.5 (85th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -565.5%)
- Cash burnNegative free cash flow (-129.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +144%/yr over 4y (dilution, book value/share -97%)
- Strong balance sheetStrong balance sheet — $296M cash & investments, ~9 quarters of runway
- Trial resultPositive trial readout — primary endpoint met (8-K) 8-K ↗
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 8 open-market sale(s) by 3 insider(s) (cluster of 3 insiders, ~$1M, last 6mo) Form 4 ↗
- Revenue declineRevenue -32.6% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-621.1%
Net margin
-565.5%
Return on equity
-47.0%
Return on assets
-38.1%
Revenue growth (QoQ)
-32.6%
Net-income growth
-319.0%
Current ratio
12.5×
Free cash flow
-$130M
Tangible book value
$306M
Cash & investments
$296M
Cash runway
9q
Stock comp / revenue
77.1%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-05-20 | Zeiher Bernhardt G | Buy | 5.0K | $5.86 |
| 2026-05-04 | Sethuraman Natarajan | Sell | 26K | $15.39 |
| 2026-05-04 | Dowden Nathan J | Sell | 15K | $15.33 |
| 2026-05-04 | Dowden Nathan J | Option exercise | 15K | $1.74 |
| 2026-04-01 | WENTWORTH KORY JAMES | Sell | 2.5K | $12.95 |
| 2026-03-10 | Dowden Nathan J | Sell | 12K | $13.05 |
| 2026-03-10 | WENTWORTH KORY JAMES | Sell | 11K | $13.02 |
| 2026-03-09 | Dowden Nathan J | Sell | 3.1K | $13.02 |
| 2026-03-09 | WENTWORTH KORY JAMES | Sell | 5.1K | $13.00 |
| 2026-03-04 | WENTWORTH KORY JAMES | Sell | 8.0K | $12.25 |
| 2026-03-03 | WENTWORTH KORY JAMES | Tax withheld | 5.7K | $11.76 |
| 2026-03-03 | Doshi Dipal | Tax withheld | 19K | $11.76 |
| 2026-03-03 | Sethuraman Natarajan | Tax withheld | 7.6K | $11.76 |
| 2026-03-03 | Dowden Nathan J | Tax withheld | 14K | $11.76 |
| 2026-03-02 | Dowden Nathan J | Tax withheld | 7.2K | $11.66 |
| 2026-03-02 | WENTWORTH KORY JAMES | Tax withheld | 2.9K | $11.66 |
| 2026-03-02 | Doshi Dipal | Tax withheld | 9.9K | $11.66 |
| 2026-03-02 | Sethuraman Natarajan | Tax withheld | 3.9K | $11.66 |
| 2026-03-01 | WENTWORTH KORY JAMES | Grant | 45K | — |
| 2026-03-01 | Sethuraman Natarajan | Grant | 56K | — |
| 2026-03-01 | Dowden Nathan J | Grant | 56K | — |
| 2026-03-01 | Doshi Dipal | Grant | 139K | — |
| 2025-11-21 | WENTWORTH KORY JAMES | Sell | 8.9K | $9.98 |
| 2025-11-20 | BAKER BROS. ADVISORS LP | Buy | 1.2K | $9.07 |
| 2025-11-20 | BAKER BROS. ADVISORS LP | Buy | 13K | $9.07 |
| 2025-11-20 | BAKER BROS. ADVISORS LP | Buy | 1.2K | $9.07 |
| 2025-11-20 | BAKER BROS. ADVISORS LP | Buy | 13K | $9.07 |
| 2025-11-14 | PARMAR KUSH | Sell | 200K | $8.80 |
| 2025-11-14 | 5AM Ventures V, L.P. | Sell | 200K | $8.80 |
| 2025-11-12 | BAKER BROS. ADVISORS LP | Buy | 11K | $7.95 |
| 2025-11-12 | BAKER BROS. ADVISORS LP | Buy | 1.0K | $7.95 |
| 2025-11-12 | BAKER BROS. ADVISORS LP | Buy | 81K | $7.73 |
| 2025-11-12 | BAKER BROS. ADVISORS LP | Buy | 7.3K | $7.73 |
| 2025-11-11 | BAKER BROS. ADVISORS LP | Buy | 2.8K | $7.54 |
| 2025-11-11 | BAKER BROS. ADVISORS LP | Buy | 1.1K | $7.39 |
| 2025-11-11 | BAKER BROS. ADVISORS LP | Buy | 12K | $7.39 |
| 2025-11-11 | BAKER BROS. ADVISORS LP | Buy | 31K | $7.54 |
| 2025-11-10 | BAKER BROS. ADVISORS LP | Buy | 2.9K | $7.22 |
| 2025-11-10 | BAKER BROS. ADVISORS LP | Buy | 267 | $7.22 |
| 2025-11-10 | BAKER BROS. ADVISORS LP | Buy | 25K | $7.21 |
| 2025-11-10 | BAKER BROS. ADVISORS LP | Buy | 2.3K | $7.21 |
| 2025-09-02 | Sethuraman Natarajan | Tax withheld | 1.8K | $5.43 |
| 2025-09-02 | Dowden Nathan J | Tax withheld | 1.7K | $5.43 |
| 2025-09-02 | WENTWORTH KORY JAMES | Tax withheld | 1.7K | $5.43 |
| 2025-09-02 | Doshi Dipal | Tax withheld | 8.7K | $5.43 |
| 2025-07-09 | PARMAR KUSH | Sell | 20K | $7.50 |
| 2025-07-09 | PARMAR KUSH | Sell | 6.9K | $7.50 |
| 2025-07-09 | 5AM Ventures V, L.P. | Sell | 20K | $7.50 |
| 2025-07-09 | 5AM Ventures V, L.P. | Sell | 6.9K | $7.50 |
| 2025-07-01 | PARMAR KUSH | Sell | 6.4K | $7.12 |
| 2025-07-01 | PARMAR KUSH | Sell | 19K | $7.12 |
| 2025-07-01 | 5AM Ventures V, L.P. | Sell | 19K | $7.12 |
| 2025-07-01 | 5AM Ventures V, L.P. | Sell | 6.4K | $7.12 |
| 2025-06-30 | 5AM Ventures V, L.P. | Sell | 19K | $6.81 |
| 2025-06-30 | 5AM Ventures V, L.P. | Sell | 6.4K | $6.81 |
| 2025-06-30 | PARMAR KUSH | Sell | 6.4K | $6.81 |
| 2025-06-30 | PARMAR KUSH | Sell | 19K | $6.81 |
| 2025-06-27 | PARMAR KUSH | Sell | 19K | $6.91 |
| 2025-06-27 | PARMAR KUSH | Sell | 56K | $6.91 |
| 2025-06-27 | 5AM Ventures V, L.P. | Sell | 56K | $6.91 |
| 2025-06-27 | 5AM Ventures V, L.P. | Sell | 19K | $6.91 |
| 2025-04-03 | WENTWORTH KORY JAMES | Option exercise | 11K | $2.10 |
| 2025-03-17 | WENTWORTH KORY JAMES | Sell | 1.8K | $10.67 |
| 2025-03-03 | Doshi Dipal | Tax withheld | 18K | $11.68 |
| 2025-03-03 | Dowden Nathan J | Tax withheld | 5.1K | $11.68 |
| 2025-03-03 | Sethuraman Natarajan | Tax withheld | 6.1K | $11.68 |
| 2025-03-03 | WENTWORTH KORY JAMES | Tax withheld | 4.9K | $11.68 |
| 2025-03-01 | Sethuraman Natarajan | Grant | 61K | — |
| 2025-03-01 | WENTWORTH KORY JAMES | Grant | 42K | — |
| 2025-03-01 | Dowden Nathan J | Grant | 61K | — |
| 2025-03-01 | Doshi Dipal | Grant | 116K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07037862 ↗ | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 Duchenne Muscular Dystrophy (DMD) | PHASE1/PHASE2 | Recruiting | 2029-03-28 |
| NCT07038824 ↗ | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 Duchenne Muscular Dystrophy (DMD) | PHASE1/PHASE2 | Recruiting | 2029-03-01 |
| NCT04245917 ↗ | Natural History Study of MNGIE Mitochondrial Neurogastrointestinal Encephalomyopathy | — | Suspended | 2025-02-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-10 | Exec/director changeShareholder voteExhibits | filing ↗ |
| 2026-05-19 | Reg FDExhibits | filing ↗ |
| 2026-05-07 | ResultsReg FDExhibits | filing ↗ |
| 2026-02-26 | ResultsExhibits | filing ↗ |
| 2026-01-08 | ResultsReg FDOther | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
| 2025-08-06 | ResultsExhibits | filing ↗ |
| 2025-06-11 | Shareholder vote | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-10 | 2026-06-10 | 0001104659-26-072326 ↗ |
| 8-K | 2026-05-19 | 2026-05-18 | 0001104659-26-063325 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001689375-26-000028 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001689375-26-000027 ↗ |
| 10-K | 2026-02-26 | 2025-12-31 | 0001689375-26-000011 ↗ |
| 8-K | 2026-02-26 | 2026-02-26 | 0001689375-26-000009 ↗ |
| 8-K | 2026-01-08 | 2026-01-08 | 0001689375-26-000003 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001689375-25-000049 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001689375-25-000050 ↗ |
| 10-Q | 2025-08-06 | 2025-06-30 | 0001689375-25-000043 ↗ |
| 8-K | 2025-08-06 | 2025-08-06 | 0001689375-25-000041 ↗ |
| 8-K | 2025-06-11 | 2025-06-11 | 0001104659-25-058536 ↗ |